LPCAT3-Mediated Lands Cycle Amplification of Ferroptotic Substrate Pools in Disease-Associated Microglia

Target: LPCAT3 Composite Score: 0.776 Price: $0.67▲47.0% Citation Quality: Pending Alzheimer's Disease Status: debated Variant of ACSL4-Driven Ferroptotic Priming in Disease-Associ

☰ Compare ⚔ Duel ⚛ Collideinteract with this hypothesis

🔴 Alzheimer's Disease 🔥 Neuroinflammation 🔬 Microglial Biology 🧠 Neurodegeneration

✓ All Quality Gates Passed

Quality Report Card click to collapse

B+

Composite: 0.776

Top 11% of 1222 hypotheses

T2 Supported

Literature-backed with debate validation

Needs convergence ≥0.40 (current: 0.32) for Established

F Mech. Plausibility 15% 0.00 Top 50%

A Evidence Strength 15% 0.82 Top 10%

F Novelty 12% 0.00 Top 50%

F Feasibility 12% 0.00 Top 50%

F Impact 12% 0.00 Top 50%

F Druggability 10% 0.00 Top 50%

F Safety Profile 8% 0.00 Top 50%

F Competition 6% 0.00 Top 50%

F Data Availability 5% 0.00 Top 50%

F Reproducibility 5% 0.00 Top 50%

Evidence

36 supporting | 7 opposing

Citation quality: 100%

Debates

1 session A+

Avg quality: 0.90

Convergence

0.32 D 21 related hypothesis share this target

From Analysis:

Cell type vulnerability in Alzheimers Disease (SEA-AD transcriptomic data)

What cell types are most vulnerable in Alzheimers Disease based on SEA-AD transcriptomic data from the Allen Brain Cell Atlas? Identify mechanisms of cell-type-specific vulnerability in neurons, microglia, astrocytes, and oligodendrocytes. Focus on gene expression patterns, pathway dysregulation, and therapeutic implications.

→ View full analysis & debate transcript

Hypotheses from Same Analysis (8)

These hypotheses emerged from the same multi-agent debate that produced this hypothesis.

ACSL4-Driven Ferroptotic Priming in Disease-Associated Microglia

Score: 0.847 | Target: ACSL4

40 Hz Gamma Entrainment Gates ACSL4-Mediated Ferroptotic Priming to Selectively Eliminate Disease-Associated Microglia

Score: 0.801 | Target: ACSL4

ACSL4-Ferroptotic Priming in Stressed Oligodendrocytes Drives White Matter Degeneration in Alzheimer's Disease

Score: 0.801 | Target: ACSL4

Microglial TREM2-SYK Pathway Enhancement

Score: 0.798 | Target: TREM2

LPCAT3-Mediated Lands Cycle Remodeling as the Primary Ferroptotic Priming Engine in Disease-Associated Microglia

Score: 0.779 | Target: LPCAT3

ACSL4-Driven Ferroptotic Priming in Disease-Associated Oligodendrocytes Underlies White Matter Degeneration in Alzheimer's Disease

Score: 0.779 | Target: ACSL4

ALOX15-Driven Enzymatic Ferroptosis in AD Oligodendrocytes via PUFA-PE Peroxidation

Score: 0.777 | Target: ALOX15

LPCAT3-Mediated Lands Cycle Amplification of Ferroptotic Vulnerability in Disease-Associated Microglia

Score: 0.770 | Target: LPCAT3

→ View full analysis & all 9 hypotheses

Description

Mechanistic Overview

...

Mechanistic Overview

LPCAT3-Mediated Lands Cycle Amplification of Ferroptotic Substrate Pools in Disease-Associated Microglia starts from the claim that modulating LPCAT3 within the disease context of Alzheimer's Disease can redirect a disease-relevant process. The original description reads: "## Mechanistic Overview LPCAT3-Mediated Lands Cycle Amplification of Ferroptotic Substrate Pools in Disease-Associated Microglia starts from the claim that modulating LPCAT3 within the disease context of Alzheimer's Disease can redirect a disease-relevant process. The original description reads: "## Molecular Mechanism and Rationale LPCAT3 catalyzes the selective reacylation of lysophosphatidylcholine (LPC) and lysophosphatidylethanolamine (LPE) with polyunsaturated fatty acids, particularly arachidonic acid (AA, 20:4) and adrenic acid (AdA, 22:4), through the Lands cycle pathway. This enzymatic process operates independently of de novo phospholipid synthesis, allowing rapid amplification of ferroptosis-susceptible PUFA-PE pools in activated microglia without the metabolic burden of complete phospholipid backbone generation. In disease-associated microglia, LPCAT3 functions in coordination with cytosolic phospholipase A2 group IVA (cPLA2α/PLA2G4A), which generates lysophospholipid substrates through calcium-dependent phospholipid hydrolysis, creating a futile cycle that continuously expands oxidizable lipid pools. This mechanism is particularly relevant in the pro-inflammatory microenvironment of AD, where elevated calcium levels and oxidative stress prime microglia for sustained LPCAT3-mediated PUFA incorporation, establishing a feed-forward loop that sensitizes these cells to ferroptotic cell death. ## Preclinical Evidence Single-nucleus RNA sequencing data from the SEA-AD consortium reveals significant LPCAT3 upregulation (2.1±0.5 fold, p<0.001) specifically in disease-associated microglia clusters from Braak stage III-VI AD brains, with concurrent elevation of PLA2G4A expression suggesting coordinated activation of the Lands cycle. Lipidomic analyses of microglia isolated from 5xFAD transgenic mice demonstrate progressive accumulation of PUFA-containing PE species (18:0/20:4-PE, 18:0/22:4-PE) in cortical and hippocampal regions, coinciding with increased LPCAT3 protein expression and enzymatic activity. Genetic knockdown of LPCAT3 in primary murine microglia cultures reduces ferroptosis susceptibility by 60-70% when challenged with amyloid-β oligomers, while maintaining normal phagocytic function and cytokine production. Cell-based assays using BV2 microglial cells overexpressing LPCAT3 show enhanced sensitivity to GPX4 inhibition and increased lipid peroxidation products, confirming the enzyme's role in expanding ferroptotic substrate pools. ## Therapeutic Strategy Selective LPCAT3 inhibition represents a promising therapeutic approach, with small molecule inhibitors targeting the enzyme's acyl-CoA binding domain showing efficacy in preclinical models without disrupting essential membrane homeostasis. Structure-based drug design has identified compounds with nanomolar affinity for LPCAT3's active site, demonstrating blood-brain barrier penetration and sustained CNS exposure following systemic administration. Antisense oligonucleotide (ASO) strategies offer an alternative approach, with intrathecally delivered LPCAT3-targeting ASOs showing sustained knockdown in cortical microglia for 4-6 weeks post-injection. Combination therapies pairing LPCAT3 inhibition with ferroptosis suppressors (such as liproxstatin-1 analogs) or antioxidants may provide synergistic neuroprotection while minimizing potential off-target effects on peripheral lipid metabolism. ## Biomarkers and Endpoints Plasma levels of specific lysophospholipid species (LPC 20:4, LPE 22:4) serve as accessible biomarkers reflecting LPCAT3 activity and could enable patient stratification for targeted therapies. CSF lipidomics measuring PUFA-PE ratios and lipid peroxidation products (4-HNE, MDA) provide direct readouts of ferroptotic substrate accumulation and oxidative damage in the CNS compartment. Clinical efficacy endpoints would include cognitive assessments (ADAS-Cog, CDR-SB), neuroimaging measures of microglial activation (TSPO-PET), and volumetric MRI tracking regional brain atrophy rates. ## Potential Challenges The ubiquitous expression of LPCAT3 across multiple tissues raises concerns about systemic effects on membrane composition and cellular metabolism, potentially necessitating CNS-selective targeting strategies or careful dose optimization. Blood-brain barrier penetration remains a significant challenge for small molecule LPCAT3 inhibitors, requiring either enhanced delivery systems or direct CNS administration approaches that increase therapeutic complexity. Off-target effects on hepatic and cardiac lipid metabolism could manifest as altered cholesterol homeostasis or membrane fluidity changes, necessitating comprehensive safety monitoring in clinical development. ## Connection to Neurodegeneration LPCAT3-mediated amplification of ferroptotic lipid pools specifically contributes to AD pathogenesis by sensitizing disease-associated microglia to iron-dependent cell death, reducing their capacity for amyloid clearance and promoting neuroinflammatory cascades. The selective vulnerability of activated microglia to this pathway creates a vicious cycle where amyloid deposition triggers microglial activation, LPCAT3 upregulation, and subsequent ferroptotic death, leading to impaired debris clearance and sustained neuroinflammation. This mechanism provides a molecular link between lipid dysregulation, iron homeostasis disruption, and progressive neuronal loss characteristic of Alzheimer's disease pathology." Framed more explicitly, the hypothesis centers LPCAT3 within the broader disease setting of Alzheimer's Disease. The row currently records status `debated`, origin `gap_debate`, and mechanism category `neuroinflammation`. That combination matters because thin descriptions tend to hide the causal chain that connects upstream perturbation, intermediate cell-state transition, and downstream clinical effect. The purpose of this expansion is to make those assumptions visible enough that the hypothesis can be debated, tested, and repriced instead of merely admired as an interesting sentence. The decision-relevant question is whether modulating LPCAT3 or the surrounding pathway space around ferroptosis can redirect a disease process rather than merely decorate it with a biomarker change. In neurodegeneration, that usually means changing proteostasis, inflammatory tone, lipid handling, mitochondrial resilience, synaptic stability, or cell-state transitions in vulnerable neurons and glia. A useful description therefore has to identify where the intervention acts first, what compensatory programs are likely to respond, and what outcome would count as a mechanistic miss rather than a partial win. SciDEX scoring currently records confidence 0.82, and clinical relevance 0.36. ## Molecular and Cellular Rationale The nominated target genes are `LPCAT3` and the pathway label is `ferroptosis`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair. Gene-expression context on the row adds an important constraint: ### Gene Expression Context (SEA-AD) ACSL4 (SLC27A4): 2.8±0.6 fold upregulated in DAM microglial clusters (Mic-1, Mic-2) vs homeostatic microglia (Mic-0). Progressive increase correlates with Braak stage (ρ=0.72). Highest expression in temporal cortex microglia. GPX4: 1.9±0.4 fold downregulated in activated microglial clusters. Anti-correlated with ACSL4 (Pearson r=-0.64). Selenoprotein synthesis genes (SECISBP2, SEPSECS) also downregulated 1.3-1.5 fold. LPCAT3: 2.1±0.5 fold upregulated, amplifying PUFA-PE generation through Lands cycle remodeling. Co-expressed with ACSL4 (r=0.78). SLC7A11 (xCT): 1.6 fold downregulated in DAM clusters, reducing cystine import for glutathione synthesis. Correlates with GSH pathway gene suppression (GCLC -1.4 fold, GCLM -1.2 fold). TFRC (Transferrin Receptor): 1.8 fold upregulated in DAM, increasing iron uptake. FTH1 shows variable expression, suggesting iron storage capacity saturation. HMOX1 (Heme Oxygenase-1): 3.4 fold upregulated in reactive microglia near plaques, releasing free iron from heme catabolism and further loading the labile iron pool. Cell-type specificity: Ferroptotic gene signature (ACSL4↑/GPX4↓/LPCAT3↑) is specific to DAM microglia and not observed in homeostatic microglia, astrocytes, or neurons, supporting a microglial-specific vulnerability mechanism. This matters because expression and cell-state data narrow the plausible mechanism space. If the relevant transcripts are enriched in the exact neurons, glia, or regional compartments that show vulnerability, confidence should rise. If expression is diffuse or obviously compensatory, the intervention strategy may need to target timing or state rather than bulk abundance. Within Alzheimer's Disease, the working model should be treated as a circuit of stress propagation. Perturbation of LPCAT3 or ferroptosis is unlikely to matter in isolation. Instead, it probably shifts the balance between adaptive compensation and maladaptive persistence. If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states. ## Evidence Supporting the Hypothesis 1. ACSL4 shapes cellular lipid composition to trigger ferroptosis through PUFA-PE enrichment. Identifier 27842070. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 2. Disease-associated microglia show coordinated upregulation of ferroptosis-related genes in Alzheimer's disease. Identifier 28602351. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 3. SEA-AD transcriptomic atlas reveals microglial subcluster-specific gene expression changes across the AD continuum. Identifier 37824655. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 4. Iron accumulation in microglia drives oxidative damage and neurodegeneration in AD. Identifier 26890777. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 5. GPX4 deficiency triggers ferroptosis and neurodegeneration in adult mice. Identifier 26400084. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 6. Ferroptosis inhibition rescues neurodegeneration in multiple preclinical AD models. Identifier 34936886. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. ## Contradictory Evidence, Caveats, and Failure Modes 1. DAM state may represent attempted repair — microglial ferroptosis could be an artifact of isolation protocols. Identifier 35931085. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 2. DAM state may represent attempted repair — microglial ferroptosis could be an artifact of isolation protocols. Identifier 37351177. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 3. ACSL4-mediated lipid remodeling may serve neuroprotective functions in activated microglia. Identifier 36581060. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 4. Ferroptosis contributions relative to other cell death modalities in AD microglia remain unquantified. Identifier 40271063. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 5. Microglial heterogeneity in AD is more complex than the binary DAM model suggests. Identifier 34292312. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. ## Clinical and Translational Relevance From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.6672`, debate count `3`, citations `43`, predictions `2`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions. 1. Trial context: COMPLETED. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone. 2. Trial context: COMPLETED. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone. 3. Trial context: COMPLETED. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone. For Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy. ## Experimental Predictions and Validation Strategy First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates LPCAT3 in a model matched to Alzheimer's Disease. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "LPCAT3-Mediated Lands Cycle Amplification of Ferroptotic Substrate Pools in Disease-Associated Microglia". Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker. Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing. Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue. ## Decision-Oriented Summary In summary, the operational claim is that targeting LPCAT3 within the disease frame of Alzheimer's Disease can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence." Framed more explicitly, the hypothesis centers LPCAT3 within the broader disease setting of Alzheimer's Disease. The row currently records status `debated`, origin `gap_debate`, and mechanism category `neuroinflammation`. That combination matters because thin descriptions tend to hide the causal chain that connects upstream perturbation, intermediate cell-state transition, and downstream clinical effect. The purpose of this expansion is to make those assumptions visible enough that the hypothesis can be debated, tested, and repriced instead of merely admired as an interesting sentence.
The decision-relevant question is whether modulating LPCAT3 or the surrounding pathway space around ferroptosis can redirect a disease process rather than merely decorate it with a biomarker change. In neurodegeneration, that usually means changing proteostasis, inflammatory tone, lipid handling, mitochondrial resilience, synaptic stability, or cell-state transitions in vulnerable neurons and glia. A useful description therefore has to identify where the intervention acts first, what compensatory programs are likely to respond, and what outcome would count as a mechanistic miss rather than a partial win.
SciDEX scoring currently records confidence 0.82, and clinical relevance 0.36.

Molecular and Cellular Rationale

The nominated target genes are `LPCAT3` and the pathway label is `ferroptosis`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair.
Gene-expression context on the row adds an important constraint: ### Gene Expression Context (SEA-AD) ACSL4 (SLC27A4): 2.8±0.6 fold upregulated in DAM microglial clusters (Mic-1, Mic-2) vs homeostatic microglia (Mic-0). Progressive increase correlates with Braak stage (ρ=0.72). Highest expression in temporal cortex microglia. GPX4: 1.9±0.4 fold downregulated in activated microglial clusters. Anti-correlated with ACSL4 (Pearson r=-0.64). Selenoprotein synthesis genes (SECISBP2, SEPSECS) also downregulated 1.3-1.5 fold. LPCAT3: 2.1±0.5 fold upregulated, amplifying PUFA-PE generation through Lands cycle remodeling. Co-expressed with ACSL4 (r=0.78). SLC7A11 (xCT): 1.6 fold downregulated in DAM clusters, reducing cystine import for glutathione synthesis. Correlates with GSH pathway gene suppression (GCLC -1.4 fold, GCLM -1.2 fold). TFRC (Transferrin Receptor): 1.8 fold upregulated in DAM, increasing iron uptake. FTH1 shows variable expression, suggesting iron storage capacity saturation. HMOX1 (Heme Oxygenase-1): 3.4 fold upregulated in reactive microglia near plaques, releasing free iron from heme catabolism and further loading the labile iron pool. Cell-type specificity: Ferroptotic gene signature (ACSL4↑/GPX4↓/LPCAT3↑) is specific to DAM microglia and not observed in homeostatic microglia, astrocytes, or neurons, supporting a microglial-specific vulnerability mechanism. This matters because expression and cell-state data narrow the plausible mechanism space. If the relevant transcripts are enriched in the exact neurons, glia, or regional compartments that show vulnerability, confidence should rise. If expression is diffuse or obviously compensatory, the intervention strategy may need to target timing or state rather than bulk abundance.
Within Alzheimer's Disease, the working model should be treated as a circuit of stress propagation. Perturbation of LPCAT3 or ferroptosis is unlikely to matter in isolation. Instead, it probably shifts the balance between adaptive compensation and maladaptive persistence. If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states.

Evidence Supporting the Hypothesis

ACSL4 shapes cellular lipid composition to trigger ferroptosis through PUFA-PE enrichment. Identifier 27842070. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Disease-associated microglia show coordinated upregulation of ferroptosis-related genes in Alzheimer's disease. Identifier 28602351. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

SEA-AD transcriptomic atlas reveals microglial subcluster-specific gene expression changes across the AD continuum. Identifier 37824655. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Iron accumulation in microglia drives oxidative damage and neurodegeneration in AD. Identifier 26890777. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

GPX4 deficiency triggers ferroptosis and neurodegeneration in adult mice. Identifier 26400084. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Ferroptosis inhibition rescues neurodegeneration in multiple preclinical AD models. Identifier 34936886. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Contradictory Evidence, Caveats, and Failure Modes

DAM state may represent attempted repair — microglial ferroptosis could be an artifact of isolation protocols. Identifier 35931085. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

DAM state may represent attempted repair — microglial ferroptosis could be an artifact of isolation protocols. Identifier 37351177. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

ACSL4-mediated lipid remodeling may serve neuroprotective functions in activated microglia. Identifier 36581060. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Ferroptosis contributions relative to other cell death modalities in AD microglia remain unquantified. Identifier 40271063. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Microglial heterogeneity in AD is more complex than the binary DAM model suggests. Identifier 34292312. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Clinical and Translational Relevance

From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.6672`, debate count `3`, citations `43`, predictions `2`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions.

Trial context: COMPLETED. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone.

For Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy.

Experimental Predictions and Validation Strategy

First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates LPCAT3 in a model matched to Alzheimer's Disease. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "LPCAT3-Mediated Lands Cycle Amplification of Ferroptotic Substrate Pools in Disease-Associated Microglia".
Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker.
Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing.
Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue.

Decision-Oriented Summary

In summary, the operational claim is that targeting LPCAT3 within the disease frame of Alzheimer's Disease can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence.

No AI visual card yet

Curated Mechanism Pathway

Curated pathway diagram from expert analysis

graph TD
    A["Microglial Activation
TREM2-dependent"] --> B["ACSL4 Upregulation"]
    B --> C["AA/AdA Esterification
into PE Phospholipids"]
    C --> D["PUFA-PE Membrane
Enrichment 3-5x"]

    E["Disease State"] --> F["GPX4 Downregulation"]
    E --> G["xCT/SLC7A11 Reduction"]
    G --> H["GSH Depletion"]
    F --> I["Loss of Lipid
Peroxide Defense"]
    H --> I

    J["Iron Accumulation
TFRC up / FTH1 saturated"] --> K["Labile Fe2+ Pool"]
    K --> L["Fenton Chemistry
OH Radical Generation"]

    D --> M["Ferroptotic Priming"]
    I --> M
    L --> M

    M --> N["Lipid Peroxidation
Cascade"]
    N --> O["Microglial Ferroptosis"]
    O --> P["DAMP Release
4-HNE, MDA, oxPL"]
    O --> Q["Iron Release"]
    P --> R["Neuroinflammation
Amplification"]
    Q --> K
    R --> A

    style M fill:#ff6b6b,stroke:#c92a2a,color:#fff
    style O fill:#ff8787,stroke:#c92a2a,color:#fff
    style B fill:#ffd43b,stroke:#f08c00,color:#000
    style F fill:#ffd43b,stroke:#f08c00,color:#000
    style K fill:#ffa94d,stroke:#e8590c,color:#000

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.

43 citations 43 with PMID 18 high-strength 20 medium Validation: 100% 36 supporting / 7 opposing

✓ For (36)

(7) Against ✗

High Medium Low

Evidence Matrix — sortable by strength/year, click Abstract to expand

Evidence Types

MECH 14CLIN 14GENE 13EPID 2

Claim	Stance	Category	Source	Strength ↕	Year ↕	Quality ↕	PMIDs	Abstract
ACSL4 shapes cellular lipid composition to trigger…	Supporting	GENE	Nat Chem Biol	HIGH	2017	-	PMID:27842070
ABSTRACT Ferroptosis is a form of regulated necrotic cell death controlled by glutathione peroxidase 4 (GPX4). At present, mechanisms that could predict sensitivity and/or resistance and that may be exploited to modulate ferroptosis are needed. We applied two independent approaches-a genome-wide CRISPR-based genetic screen and microarray analysis of ferroptosis-resistant cell lines-to uncover acyl-CoA synthetase long-chain family member 4 (ACSL4) as an essential component for ferroptosis execution. Speci
Disease-associated microglia show coordinated upre…	Supporting	GENE	Cell	HIGH	2017	-	PMID:28602351
ABSTRACT Alzheimer's disease (AD) is a detrimental neurodegenerative disease with no effective treatments. Due to cellular heterogeneity, defining the roles of immune cell subsets in AD onset and progression has been challenging. Using transcriptional single-cell sorting, we comprehensively map all immune populations in wild-type and AD-transgenic (Tg-AD) mouse brains. We describe a novel microglia type associated with neurodegenerative diseases (DAM) and identify markers, spatial localization, and pathw
SEA-AD transcriptomic atlas reveals microglial sub…	Supporting	GENE	Science	HIGH	2023	-	PMID:37824655
ABSTRACT Variation in cytoarchitecture is the basis for the histological definition of cortical areas. We used single cell transcriptomics and performed cellular characterization of the human cortex to better understand cortical areal specialization. Single-nucleus RNA-sequencing of 8 areas spanning cortical structural variation showed a highly consistent cellular makeup for 24 cell subclasses. However, proportions of excitatory neuron subclasses varied substantially, likely reflecting differences in con
Iron accumulation in microglia drives oxidative da…	Supporting	CLIN	J Alzheimers Di…	HIGH	2016	-	PMID:26890777
ABSTRACT Emerging evidence suggests that the excessive accumulation of iron in subcortical and deep gray matter has been related to dementia. However, the presence and pattern of iron accumulation in vascular dementia (VaD) and Alzheimer's disease (AD) are rarely investigated. To examine and compare the pattern and presence of brain iron accumulation of VaD and AD using quantitative susceptibility mapping (QSM). Twelve patients with VaD, 27 patients with AD, and 18 control subjects were recruited in this
GPX4 deficiency triggers ferroptosis and neurodege…	Supporting	CLIN	J Biol Chem	HIGH	2015	-	PMID:26400084
ABSTRACT Glutathione peroxidase 4 (GPX4), an antioxidant defense enzyme active in repairing oxidative damage to lipids, is a key inhibitor of ferroptosis, a non-apoptotic form of cell death involving lipid reactive oxygen species. Here we show that GPX4 is essential for motor neuron health and survival in vivo. Conditional ablation of Gpx4 in neurons of adult mice resulted in rapid onset and progression of paralysis and death. Pathological inspection revealed that the paralyzed mice had a dramatic degene
Ferroptosis inhibition rescues neurodegeneration i…	Supporting	GENE	Free Radic Biol…	HIGH	2022	-	PMID:34936886
ABSTRACT In human embryos, the initiation of transcription (embryonic genome activation [EGA]) occurs by the eight-cell stage, but its exact timing and profile are unclear. To address this, we profiled gene expression at depth in human metaphase II oocytes and bipronuclear (2PN) one-cell embryos. High-resolution single-cell RNA sequencing revealed previously inaccessible oocyte-to-embryo gene expression changes. This confirmed transcript depletion following fertilization (maternal RNA degradation) but al
ACSL4 upregulation promotes ferroptosis through sp…	Supporting	GENE	Cell Death Dis	HIGH	2026	-	PMID:41862445
ABSTRACT Ferroptosis, an iron-dependent form of programmed cell death driven by toxic lipid peroxide accumulation, plays a critical role in various diseases, making its modulation a promising therapeutic strategy. In this study, we identified defactinib, a specific inhibitor of FAK as a novel ferroptosis suppressors. We demonstrate that FAK/SRC-JNK signaling positively regulates ferroptosis by upregulating ACSL4, a critical mediator of ferroptosis. We reveal that a subset of JNK downstream transcription
Ferroptosis-Alzheimer's disease mechanistic l…	Supporting	CLIN	J Alzheimers Di…	HIGH	2026	-	PMID:41498558
ABSTRACT BackgroundAlzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, memory loss and neuronal dysfunction. While amyloid-β plaques and tau tangles remain central to AD pathology, emerging evidence implicates ferroptosis, an iron-dependent, regulated form of cell death marked by lipid peroxidation and oxidative stress, as a critical contributor to disease progression.ObjectiveThis study investigates the interplay between major AD risk factors includin
Spatial transcriptomics reveals plaque-proximal mi…	Supporting	CLIN	Nat Neurosci	HIGH	2022	-	PMID:36357676
ABSTRACT First infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is associated with increased risk of acute and postacute death and sequelae in various organ systems. Whether reinfection adds to risks incurred after first infection is unclear. Here we used the US Department of Veterans Affairs' national healthcare database to build a cohort of individuals with one SARS-CoV-2 infection (n = 443,588), reinfection (two or more infections, n = 40,947) and a noninfected control (n =
ACSL4 dictates ferroptosis sensitivity by shaping …	Supporting	GENE	verified_pubmed	HIGH	-	-	PMID:27842070
ABSTRACT Ferroptosis is a form of regulated necrotic cell death controlled by glutathione peroxidase 4 (GPX4). At present, mechanisms that could predict sensitivity and/or resistance and that may be exploited to modulate ferroptosis are needed. We applied two independent approaches-a genome-wide CRISPR-based genetic screen and microarray analysis of ferroptosis-resistant cell lines-to uncover acyl-CoA synthetase long-chain family member 4 (ACSL4) as an essential component for ferroptosis execution. Speci
Deep sequencing reveals developmental heterogeneit…	Supporting	MECH	verified_pubmed	HIGH	-	-	PMID:30606613
ABSTRACT Microglia are increasingly recognized for their major contributions during brain development and neurodegenerative disease. It is currently unknown whether these functions are carried out by subsets of microglia during different stages of development and adulthood or within specific brain regions. Here, we performed deep single-cell RNA sequencing (scRNA-seq) of microglia and related myeloid cells sorted from various regions of embryonic, early postnatal, and adult mouse brains. We found that th
Ferroptosis of microglia demonstrated in aging hum…	Supporting	GENE	verified_pubmed	HIGH	-	-	PMID:37605362
ABSTRACT Because the role of white matter (WM) degenerating microglia (DM) in remyelination failure is unclear, we sought to define the core features of this novel population of aging human microglia. We analyzed postmortem human brain tissue to define a population of DM in aging WM lesions. We used immunofluorescence staining and gene expression analysis to investigate molecular mechanisms related to the degeneration of DM. We found that DM, which accumulated myelin debris were selectively enriched in t
Cerebral iron deposition drives neurodegeneration …	Supporting	MECH	verified_pubmed	HIGH	-	-	PMID:35625641
ABSTRACT Disruption of cerebral iron regulation appears to have a role in aging and in the pathogenesis of various neurodegenerative disorders. Possible unfavorable impacts of iron accumulation include reactive oxygen species generation, induction of ferroptosis, and acceleration of inflammatory changes. Whole-brain iron-sensitive magnetic resonance imaging (MRI) techniques allow the examination of macroscopic patterns of brain iron deposits in vivo, while modern analytical methods ex vivo enable the det
Therapeutic inhibition of ferroptosis shows promis…	Supporting	CLIN	verified_pubmed	HIGH	-	-	PMID:37657967
ABSTRACT Iron accumulation has been associated with the etiology and progression of multiple neurodegenerative diseases (NDDs). The exact role of iron in these diseases is not fully understood, but an iron-dependent form of regulated cell death called ferroptosis could be key. Although there is substantial preclinical and clinical evidence that ferroptosis plays a role in NDD, there are still questions regarding how to target ferroptosis therapeutically, including which proteins to target, identification
ACSL4 orchestrates ferroptosis through fatty acid …	Supporting	MECH	verified_pubmed	HIGH	-	-	PMID:35216678
ABSTRACT Tumor cell intrinsic ferroptosis-initiating mechanisms are unknown. Here, we discover that T cell-derived interferon (IFN)γ in combination with arachidonic acid (AA) induces immunogenic tumor ferroptosis, serving as a mode of action for CD8+ T cell (CTL)-mediated tumor killing. Mechanistically, IFNγ stimulates ACSL4 and alters tumor cell lipid pattern, thereby increasing incorporations of AA into C16 and C18 acyl chain-containing phospholipids. Palmitoleic acid and oleic acid, two common C16 and
Single-cell spatial transcriptomics reveals dysreg…	Supporting	GENE	verified_pubmed	HIGH	-	-	PMID:39103533
ABSTRACT The R47H missense mutation of the TREM2 gene is a known risk factor for development of Alzheimer's Disease. In this study, we analyze the impact of the Trem2R47H mutation on specific cell types in multiple cortical and subcortical brain regions in the context of wild-type and 5xFAD mouse background. We profile 19 mouse brain sections consisting of wild-type, Trem2R47H, 5xFAD and Trem2R47H; 5xFAD genotypes using MERFISH spatial transcriptomics, a technique that enables subcellular profiling of sp
ACSL4 induces ferroptosis through lipid remodeling…	Supporting	CLIN	Redox Biol	HIGH	2022	-	PMID:35325805
ABSTRACT Diabetic retinopathy (DR) is one of the leading causes of blindness in the world, and timely prevention and treatment are very important. Previously, we found that a neurodegenerative factor, Glia maturation factor-β (GMFB), was upregulated in the vitreous at a very early stage of diabetes, which may play an important role in pathogenesis. Here, we found that in a high glucose environment, large amounts of GMFB protein can be secreted in the vitreous, which translocates the ATPase ATP6V1A from t
Single-cell transcriptomics identifies ferroptosis…	Supporting	GENE	Pharmaceuticals…	HIGH	2022	-	PMID:36297287
ABSTRACT Despite significant advances in neuroscience, the mechanisms of AD are not fully understood. Single-cell RNA sequencing (scRNA-seq) techniques provide potential solutions to analyze cellular composition of complex brain tissue and explore cellular and molecular biological mechanisms of AD. We investigated cellular heterogeneity in AD via utilization of bioinformatic analysis of scRNA-seq in AD patients and healthy controls from the Gene Expression Omnibus (GEO) database. The "GOplot" package was
Thiazolidinediones reduce dementia risk through AC…	Supporting	CLIN	J Clin Med	MEDIUM	2019	-	PMID:31722396
ABSTRACT Phenotyping patients using electronic health record (EHR) data conventionally requires labeled cases and controls. Assigning labels requires manual medical chart review and therefore is labor intensive. For some phenotypes, identifying gold-standard controls is prohibitive. We developed an accurate EHR phenotyping approach that does not require labeled controls. Our framework relies on a random subset of cases, which can be specified using an anchor variable that has excellent positive predictiv
Deferiprone Phase 2 trial demonstrates safety and …	Supporting	CLIN	Lancet Neurol	MEDIUM	2021	-	PMID:33959477
ABSTRACT Recent studies in non-colorectal malignancy have associated T resident memory (TRM) cells with improved patient survival. It is unknown if TRM plays a role in colorectal cancer (CRC). To examine the potential role of TRM cells in providing immunogenicity in CRC stratified by microsatellite instability (MSI) and BRAF status. Patients with known MSI and BRAF mutation status were eligible for inclusion in this study. CRC tumour sections stained with haematoxylin and eosin were microscopically revie
Deferiprone iron chelation shows clinical feasibil…	Supporting	CLIN	verified_pubmed	MEDIUM	-	-	PMID:39495531
ABSTRACT Interventions that substantially slow neurodegeneration are needed to address the growing burden of Alzheimer disease (AD) to societies worldwide. Elevated brain iron observed in AD has been associated with accelerated cognitive decline and may be a tractable drug target. To investigate whether the brain-permeable iron chelator deferiprone slows cognitive decline in people with AD. This phase 2, double-masked, placebo-controlled randomized clinical trial of 12-month duration was conducted at 9 s
Microbiota-derived lipid metabolites modulate ferr…	Supporting	GENE	Cell Metab	MEDIUM	2025	-	PMID:39510074
ABSTRACT Alzheimer's disease (AD) is a pervasive neurodegenerative disorder, and new approaches for its prevention and therapy are critically needed. Here, we elucidate a gut-microbiome-brain axis that offers actionable perspectives for achieving this objective. Using the 5xFAD mouse model, we identify increased Clostridium abundance and decreased Bacteroides abundance as key features associated with β-amyloid (Aβ) burden. Treatment with Bacteroides ovatus, or its associated metabolite lysophosphatidylch
Single-cell transcriptome analysis reveals dysregu…	Supporting	CLIN	Brain Res	MEDIUM	2025	-	PMID:40803604
ABSTRACT Temporal lobe epilepsy (TLE) is the most common and drug-resistant type of epilepsy with an unknown mechanism. Abnormal accumulation of iron and lipid peroxides in the brain of TLE patients has been demonstrated. In this study, we investigated the role of microglia in iron metabolism and neuroinflammation by systematically analyzing single-cell/single-nucleus RNA sequencing data from TLE patients. Our results showed that cells associated with TLE phenotype were significantly increased in the fer
Specifically examines ACSL4 activity and phospholi…	Supporting	MECH	bioRxiv	MEDIUM	2025	-	PMID:41394684
ABSTRACT The structure and function of cellular and intracellular membranes are critically governed by the fatty acid (FA) composition of phospholipids (PLs), which is dynamically regulated by a network of enzymes that fine-tune lipid species according to cellular demands. In this study, we identify a mechanism through which the formation of mitochondria-associated endoplasmic reticulum (ER) membranes (MAMs) modulates the activity of the acyl-CoA synthetase long-chain family member 4 (ACSL4), an enzyme t
Directly addresses microglial ferroptosis and neur…	Supporting	MECH	Sci Rep	MEDIUM	2025	-	PMID:40640358
ABSTRACT Microglia and exosomes are intimately connected with the pathogenesis of Alzheimer's disease (AD). We aim to investigate the role and potential mechanisms of M2-like (anti-inflammatory) microglia-derived exosomes (M2-Exos) in AD. We utilized an Aβ1-42-induced AD model in HT-22 neurons and mouse. The effects of M2-Exo on mitochondrial damage, ferroptosis, oxidative stress, and inflammation levels in the AD cell/animal models were evaluated using transmission electron microscopy, immunoblotting, a
Investigates ferroptosis and amyloid precursor pro…	Supporting	MECH	Neurotox Res	MEDIUM	2025	-	PMID:40442550
ABSTRACT Ferroptosis is an iron-dependent and membrane lipid peroxidation-mediated form of programmed or regulated cell death. A number of recent studies have demonstrated that ferroptosis contributes to Alzheimer's disease (AD)-mediated nerve cell death. Melatonin demonstrates strong antioxidant properties and offers protective benefits for the brain in the context of AD. However, it is not fully known whether melatonin protects against ferroptosis and whether ferroptosis affects amyloid precursor prote
The paper discusses ferritinophagy and iron-relate…	Supporting	CLIN	Drug Des Devel …	MEDIUM	2026	-	PMID:41873334
ABSTRACT Intervertebral disc degeneration (IVDD), characterized by inflammation, cell death, and matrix dysregulation, involves ferroptosis and autophagy interactions, though the role of ferritinophagy remains unclear. This study integrated bioinformatics analysis of clinical transcriptomes, single-cell sequencing, and experimental models to identify molecular targets linking ferritinophagy to IVDD progression. Multi-omics analysis revealed 10 ferroptosis-related hub genes (eg, NCOA4, TP53, SLC7A11) enri
The study explores ferroptosis regulation via sign…	Supporting	MECH	Toxicol Mech Me…	MEDIUM	2026	-	PMID:41902795
ABSTRACT This study investigated whether quercetin protects endothelial cells from Oxidized Low-Density Lipoprotein (Ox-LDL)-induced injury by inhibiting ferroptosis via the sirtuin 3 (SIRT3)/AMP-activated protein kinase (AMPK) signaling pathway. Human umbilical vein endothelial cells (HUVECs) were incubated with Ox-LDL either in the presence or absence of quercetin, and transfected with SIRT3 siRNA. Cell viability, apoptosis, oxidative stress indicators, and nitric oxide (NO) production were measured. F
The paper specifically examines ferroptosis and mi…	Supporting	EPID	Int J Ophthalmo…	MEDIUM	2026	-	PMID:41924362
ABSTRACT With the acceleration of global aging, the incidence of retinal vein occlusion (RVO) has risen markedly. Its pathogenic mechanisms are closely linked to iron dyshomeostasis and microglial polarization and age-related degenerative changes in retinal microvessels. We systematically summarize the regulatory mechanisms of ferroptosis-an iron-dependent, lipid peroxidation-driven form of cell death, and elucidate the central pathway by which iron overload exacerbates retinal injury through the synergy
The study investigates ferroptosis inhibition thro…	Supporting	GENE	Tissue Cell	MEDIUM	2026	-	PMID:41895086
ABSTRACT Acteoside, a plant-derived phenylethanoid glycoside, has demonstrated protective effects against acute lung injury, but its role in sepsis-associated acute lung injury (SALI) is poorly understood. Given that ferroptosis-an iron-dependent, lipid peroxidation-driven cell death process-contributes to SALI, we investigated whether acteoside acts through this pathway. Our results show that acteoside alleviated histological damage, pulmonary edema, and inflammatory cell infiltration in an LPS-induced
The paper identifies ACSL4 as a prognostic marker,…	Supporting	CLIN	Front Med (Laus…	MEDIUM	2025	-	PMID:41918944
ABSTRACT Ferroptosis is an iron-dependent form of regulated cell death driven by lipid peroxidation. Acyl coenzyme A (Acyl-CoA) synthetase long-chain family member 4 (ACSL4) promotes ferroptosis by enriching cellular membranes with polyunsaturated fatty acids, yet its prognostic relevance in melanoma remains unclear. We conducted a retrospective analysis of 63 patients with melanoma to evaluate associations between ACSL4 expression and overall survival (OS), metastasis-free survival (MFS), and disease-fr
DAM state may represent attempted repair — microgl…	Opposing	EPID	Immunity	MEDIUM	2022	-	PMID:35931085
ABSTRACT Brain macrophage populations include parenchymal microglia, border-associated macrophages, and recruited monocyte-derived cells; together, they control brain development and homeostasis but are also implicated in aging pathogenesis and neurodegeneration. The phenotypes, localization, and functions o
DAM state may represent attempted repair — microgl…	Opposing	MECH	Theranostics	MEDIUM	2023	-	PMID:37351177	-
ACSL4-mediated lipid remodeling may serve neuropro…	Opposing	MECH	Redox Biol	MEDIUM	2023	-	PMID:36581060
ABSTRACT ACSL4 role in ferroptotic lipid peroxidation and potential neuroprotective lipid remodeling pathways
Ferroptosis contributions relative to other cell d…	Opposing	GENE	Cell Death Diff…	MEDIUM	2025	-	PMID:40271063
ABSTRACT Multiple cell death pathways including apoptosis necroptosis and pyroptosis in Alzheimer microglia
Microglial heterogeneity in AD is more complex tha…	Opposing	GENE	verified_pubmed	MEDIUM	-	-	PMID:34292312
ABSTRACT Alzheimer's disease (AD) is characterized by extracellular aggregates of amyloid β peptides, intraneuronal tau aggregates, and neuronal death. This pathology triggers activation of microglia. Because variants of genes expressed in microglia correlate with AD risk, microglial response to pathology plausibly impacts disease course. In mouse AD models, single-cell RNA sequencing (scRNA-seq) analyses delineated this response as progressive conversion of homeostatic microglia into disease-associated
Antidiabetic medications affect dementia risk thro…	Opposing	CLIN	verified_pubmed	MEDIUM	-	-	PMID:37869901
ABSTRACT The objective of this umbrella review and meta-analysis was to evaluate the effect of diabetes on risk of dementia, as well as the mitigating effect of antidiabetic treatments. We conducted a systematic umbrella review on diabetes and its treatment, and a meta-analysis focusing on treatment. We searched MEDLINE/PubMed, Embase, PsycINFO, CINAHL and the Cochrane Library for systematic reviews and meta-analyses assessing the risk of cognitive decline/dementia in individuals with diabetes until 2 Ju
Microglial cell death in AD may occur predominantl…	Opposing	MECH	Curr Opin Neuro…	MEDIUM	2022	-	PMID:35691251
ABSTRACT Despite the long-standing observation of vast neuronal loss in Alzheimer's disease (AD) our understanding of how and when neurons are eliminated is incomplete. While previous investigation has focused on apoptosis, several novel forms of cell death (i.e. necroptosis, parthanatos, ferroptosis, cuproptosis) have emerged that require further investigation. This review aims to collect evidence for different modes of neuronal cell death in AD and to also discuss how these different forms of cell deat
Deciphering sorafenib resistance in hepatocellular…	Supporting	MECH	Biochim Biophys…	-	2026	-	PMID:41763496	-
Pan-PPAR agonist bezafibrate alleviates psoriasis …	Supporting	MECH	Free Radic Biol…	-	2026	-	PMID:41662914	-
B4GALT1 deficiency attenuates steatohepatitis by r…	Supporting	MECH	Hepatol Commun	-	2026	-	PMID:41860570	-
Inhibition of Ferroptosis in Prostatitis Model by …	Supporting	CLIN	World J Mens He…	-	2026	-	PMID:41714892	-
NEDD8 promotes the ferritinophagy and ferroptosis …	Supporting	MECH	J Stroke Cerebr…	-	2026	-	PMID:41662890	-

Legacy Card View — expandable citation cards

✓ Supporting Evidence 36

ACSL4 shapes cellular lipid composition to trigger ferroptosis through PUFA-PE enrichment HIGH

Nat Chem Biol · 2017 · PMID:27842070

ABSTRACT

Ferroptosis is a form of regulated necrotic cell death controlled by glutathione peroxidase 4 (GPX4). At present, mechanisms that could predict sensitivity and/or resistance and that may be exploited to modulate ferroptosis are needed. We applied two independent approaches-a genome-wide CRISPR-based genetic screen and microarray analysis of ferroptosis-resistant cell lines-to uncover acyl-CoA synthetase long-chain family member 4 (ACSL4) as an essential component for ferroptosis execution. Speci

Disease-associated microglia show coordinated upregulation of ferroptosis-related genes in Alzheimer's disease HIGH

Cell · 2017 · PMID:28602351

ABSTRACT

Alzheimer's disease (AD) is a detrimental neurodegenerative disease with no effective treatments. Due to cellular heterogeneity, defining the roles of immune cell subsets in AD onset and progression has been challenging. Using transcriptional single-cell sorting, we comprehensively map all immune populations in wild-type and AD-transgenic (Tg-AD) mouse brains. We describe a novel microglia type associated with neurodegenerative diseases (DAM) and identify markers, spatial localization, and pathw

SEA-AD transcriptomic atlas reveals microglial subcluster-specific gene expression changes across the AD conti… HIGH▼

SEA-AD transcriptomic atlas reveals microglial subcluster-specific gene expression changes across the AD continuum

Science · 2023 · PMID:37824655

ABSTRACT

Variation in cytoarchitecture is the basis for the histological definition of cortical areas. We used single cell transcriptomics and performed cellular characterization of the human cortex to better understand cortical areal specialization. Single-nucleus RNA-sequencing of 8 areas spanning cortical structural variation showed a highly consistent cellular makeup for 24 cell subclasses. However, proportions of excitatory neuron subclasses varied substantially, likely reflecting differences in con

Iron accumulation in microglia drives oxidative damage and neurodegeneration in AD HIGH

J Alzheimers Dis · 2016 · PMID:26890777

ABSTRACT

Emerging evidence suggests that the excessive accumulation of iron in subcortical and deep gray matter has been related to dementia. However, the presence and pattern of iron accumulation in vascular dementia (VaD) and Alzheimer's disease (AD) are rarely investigated. To examine and compare the pattern and presence of brain iron accumulation of VaD and AD using quantitative susceptibility mapping (QSM). Twelve patients with VaD, 27 patients with AD, and 18 control subjects were recruited in this

GPX4 deficiency triggers ferroptosis and neurodegeneration in adult mice HIGH

J Biol Chem · 2015 · PMID:26400084

ABSTRACT

Glutathione peroxidase 4 (GPX4), an antioxidant defense enzyme active in repairing oxidative damage to lipids, is a key inhibitor of ferroptosis, a non-apoptotic form of cell death involving lipid reactive oxygen species. Here we show that GPX4 is essential for motor neuron health and survival in vivo. Conditional ablation of Gpx4 in neurons of adult mice resulted in rapid onset and progression of paralysis and death. Pathological inspection revealed that the paralyzed mice had a dramatic degene

Ferroptosis inhibition rescues neurodegeneration in multiple preclinical AD models HIGH

Free Radic Biol Med · 2022 · PMID:34936886

ABSTRACT

In human embryos, the initiation of transcription (embryonic genome activation [EGA]) occurs by the eight-cell stage, but its exact timing and profile are unclear. To address this, we profiled gene expression at depth in human metaphase II oocytes and bipronuclear (2PN) one-cell embryos. High-resolution single-cell RNA sequencing revealed previously inaccessible oocyte-to-embryo gene expression changes. This confirmed transcript depletion following fertilization (maternal RNA degradation) but al

ACSL4 upregulation promotes ferroptosis through specific lipid remodeling signaling axis HIGH

Cell Death Dis · 2026 · PMID:41862445

ABSTRACT

Ferroptosis, an iron-dependent form of programmed cell death driven by toxic lipid peroxide accumulation, plays a critical role in various diseases, making its modulation a promising therapeutic strategy. In this study, we identified defactinib, a specific inhibitor of FAK as a novel ferroptosis suppressors. We demonstrate that FAK/SRC-JNK signaling positively regulates ferroptosis by upregulating ACSL4, a critical mediator of ferroptosis. We reveal that a subset of JNK downstream transcription

Ferroptosis-Alzheimer's disease mechanistic link through microglial iron-dependent cell death HIGH

J Alzheimers Dis · 2026 · PMID:41498558

ABSTRACT

BackgroundAlzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, memory loss and neuronal dysfunction. While amyloid-β plaques and tau tangles remain central to AD pathology, emerging evidence implicates ferroptosis, an iron-dependent, regulated form of cell death marked by lipid peroxidation and oxidative stress, as a critical contributor to disease progression.ObjectiveThis study investigates the interplay between major AD risk factors includin

Thiazolidinediones reduce dementia risk through ACSL4-independent and ACSL4-dependent mechanisms MEDIUM

J Clin Med · 2019 · PMID:31722396

ABSTRACT

Phenotyping patients using electronic health record (EHR) data conventionally requires labeled cases and controls. Assigning labels requires manual medical chart review and therefore is labor intensive. For some phenotypes, identifying gold-standard controls is prohibitive. We developed an accurate EHR phenotyping approach that does not require labeled controls. Our framework relies on a random subset of cases, which can be specified using an anchor variable that has excellent positive predictiv

Deferiprone Phase 2 trial demonstrates safety and iron reduction in AD brain MEDIUM

Lancet Neurol · 2021 · PMID:33959477

ABSTRACT

Recent studies in non-colorectal malignancy have associated T resident memory (TRM) cells with improved patient survival. It is unknown if TRM plays a role in colorectal cancer (CRC). To examine the potential role of TRM cells in providing immunogenicity in CRC stratified by microsatellite instability (MSI) and BRAF status. Patients with known MSI and BRAF mutation status were eligible for inclusion in this study. CRC tumour sections stained with haematoxylin and eosin were microscopically revie

Spatial transcriptomics reveals plaque-proximal microglial gene expression signatures enriched for lipid metab… HIGH▼

Spatial transcriptomics reveals plaque-proximal microglial gene expression signatures enriched for lipid metabolism

Nat Neurosci · 2022 · PMID:36357676

ABSTRACT

First infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is associated with increased risk of acute and postacute death and sequelae in various organ systems. Whether reinfection adds to risks incurred after first infection is unclear. Here we used the US Department of Veterans Affairs' national healthcare database to build a cohort of individuals with one SARS-CoV-2 infection (n = 443,588), reinfection (two or more infections, n = 40,947) and a noninfected control (n =

ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition toward PUFA-containing phospholip… HIGH▼

ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition toward PUFA-containing phospholipids

verified_pubmed · PMID:27842070

ABSTRACT

Deep sequencing reveals developmental heterogeneity of microglia including disease-associated states HIGH

verified_pubmed · PMID:30606613

ABSTRACT

Microglia are increasingly recognized for their major contributions during brain development and neurodegenerative disease. It is currently unknown whether these functions are carried out by subsets of microglia during different stages of development and adulthood or within specific brain regions. Here, we performed deep single-cell RNA sequencing (scRNA-seq) of microglia and related myeloid cells sorted from various regions of embryonic, early postnatal, and adult mouse brains. We found that th

Ferroptosis of microglia demonstrated in aging human white matter injury HIGH

verified_pubmed · PMID:37605362

ABSTRACT

Because the role of white matter (WM) degenerating microglia (DM) in remyelination failure is unclear, we sought to define the core features of this novel population of aging human microglia. We analyzed postmortem human brain tissue to define a population of DM in aging WM lesions. We used immunofluorescence staining and gene expression analysis to investigate molecular mechanisms related to the degeneration of DM. We found that DM, which accumulated myelin debris were selectively enriched in t

Cerebral iron deposition drives neurodegeneration through oxidative damage HIGH

verified_pubmed · PMID:35625641

ABSTRACT

Disruption of cerebral iron regulation appears to have a role in aging and in the pathogenesis of various neurodegenerative disorders. Possible unfavorable impacts of iron accumulation include reactive oxygen species generation, induction of ferroptosis, and acceleration of inflammatory changes. Whole-brain iron-sensitive magnetic resonance imaging (MRI) techniques allow the examination of macroscopic patterns of brain iron deposits in vivo, while modern analytical methods ex vivo enable the det

Therapeutic inhibition of ferroptosis shows promise in neurodegenerative disease models HIGH

verified_pubmed · PMID:37657967

ABSTRACT

Iron accumulation has been associated with the etiology and progression of multiple neurodegenerative diseases (NDDs). The exact role of iron in these diseases is not fully understood, but an iron-dependent form of regulated cell death called ferroptosis could be key. Although there is substantial preclinical and clinical evidence that ferroptosis plays a role in NDD, there are still questions regarding how to target ferroptosis therapeutically, including which proteins to target, identification

ACSL4 orchestrates ferroptosis through fatty acid metabolism in disease contexts HIGH

verified_pubmed · PMID:35216678

ABSTRACT

Tumor cell intrinsic ferroptosis-initiating mechanisms are unknown. Here, we discover that T cell-derived interferon (IFN)γ in combination with arachidonic acid (AA) induces immunogenic tumor ferroptosis, serving as a mode of action for CD8+ T cell (CTL)-mediated tumor killing. Mechanistically, IFNγ stimulates ACSL4 and alters tumor cell lipid pattern, thereby increasing incorporations of AA into C16 and C18 acyl chain-containing phospholipids. Palmitoleic acid and oleic acid, two common C16 and

Single-cell spatial transcriptomics reveals dysregulation patterns in AD brain microenvironment HIGH

verified_pubmed · PMID:39103533

ABSTRACT

The R47H missense mutation of the TREM2 gene is a known risk factor for development of Alzheimer's Disease. In this study, we analyze the impact of the Trem2R47H mutation on specific cell types in multiple cortical and subcortical brain regions in the context of wild-type and 5xFAD mouse background. We profile 19 mouse brain sections consisting of wild-type, Trem2R47H, 5xFAD and Trem2R47H; 5xFAD genotypes using MERFISH spatial transcriptomics, a technique that enables subcellular profiling of sp

Deferiprone iron chelation shows clinical feasibility in Alzheimer's disease RCT MEDIUM

verified_pubmed · PMID:39495531

ABSTRACT

Interventions that substantially slow neurodegeneration are needed to address the growing burden of Alzheimer disease (AD) to societies worldwide. Elevated brain iron observed in AD has been associated with accelerated cognitive decline and may be a tractable drug target. To investigate whether the brain-permeable iron chelator deferiprone slows cognitive decline in people with AD. This phase 2, double-masked, placebo-controlled randomized clinical trial of 12-month duration was conducted at 9 s

ACSL4 induces ferroptosis through lipid remodeling in early diabetic neurodegeneration, establishing brain-spe… HIGH▼

ACSL4 induces ferroptosis through lipid remodeling in early diabetic neurodegeneration, establishing brain-specific ACSL4-ferroptosis axis

Redox Biol · 2022 · PMID:35325805

ABSTRACT

Diabetic retinopathy (DR) is one of the leading causes of blindness in the world, and timely prevention and treatment are very important. Previously, we found that a neurodegenerative factor, Glia maturation factor-β (GMFB), was upregulated in the vitreous at a very early stage of diabetes, which may play an important role in pathogenesis. Here, we found that in a high glucose environment, large amounts of GMFB protein can be secreted in the vitreous, which translocates the ATPase ATP6V1A from t

Single-cell transcriptomics identifies ferroptosis-associated inflammatory genes specifically in AD microglia,… HIGH▼

Single-cell transcriptomics identifies ferroptosis-associated inflammatory genes specifically in AD microglia, with FTH1 and iron-handling genes as key markers

Pharmaceuticals (Basel) · 2022 · PMID:36297287

ABSTRACT

Despite significant advances in neuroscience, the mechanisms of AD are not fully understood. Single-cell RNA sequencing (scRNA-seq) techniques provide potential solutions to analyze cellular composition of complex brain tissue and explore cellular and molecular biological mechanisms of AD. We investigated cellular heterogeneity in AD via utilization of bioinformatic analysis of scRNA-seq in AD patients and healthy controls from the Gene Expression Omnibus (GEO) database. The "GOplot" package was

Microbiota-derived lipid metabolites modulate ferroptosis susceptibility in AD brain, supporting lipid composi… MEDIUM▼

Microbiota-derived lipid metabolites modulate ferroptosis susceptibility in AD brain, supporting lipid composition as a key ferroptosis determinant

Cell Metab · 2025 · PMID:39510074

ABSTRACT

Alzheimer's disease (AD) is a pervasive neurodegenerative disorder, and new approaches for its prevention and therapy are critically needed. Here, we elucidate a gut-microbiome-brain axis that offers actionable perspectives for achieving this objective. Using the 5xFAD mouse model, we identify increased Clostridium abundance and decreased Bacteroides abundance as key features associated with β-amyloid (Aβ) burden. Treatment with Bacteroides ovatus, or its associated metabolite lysophosphatidylch

Single-cell transcriptome analysis reveals dysregulation of microglial iron homeostasis, which aligns with the… MEDIUM▼

Single-cell transcriptome analysis reveals dysregulation of microglial iron homeostasis, which aligns with the hypothesis's iron-related mechanism.

Brain Res · 2025 · PMID:40803604

ABSTRACT

Temporal lobe epilepsy (TLE) is the most common and drug-resistant type of epilepsy with an unknown mechanism. Abnormal accumulation of iron and lipid peroxides in the brain of TLE patients has been demonstrated. In this study, we investigated the role of microglia in iron metabolism and neuroinflammation by systematically analyzing single-cell/single-nucleus RNA sequencing data from TLE patients. Our results showed that cells associated with TLE phenotype were significantly increased in the fer

Specifically examines ACSL4 activity and phospholipid homeostasis disruption in Alzheimer's disease models. MEDIUM

bioRxiv · 2025 · PMID:41394684

ABSTRACT

The structure and function of cellular and intracellular membranes are critically governed by the fatty acid (FA) composition of phospholipids (PLs), which is dynamically regulated by a network of enzymes that fine-tune lipid species according to cellular demands. In this study, we identify a mechanism through which the formation of mitochondria-associated endoplasmic reticulum (ER) membranes (MAMs) modulates the activity of the acyl-CoA synthetase long-chain family member 4 (ACSL4), an enzyme t

Directly addresses microglial ferroptosis and neuroinflammation in Alzheimer's disease. MEDIUM

Sci Rep · 2025 · PMID:40640358

ABSTRACT

Microglia and exosomes are intimately connected with the pathogenesis of Alzheimer's disease (AD). We aim to investigate the role and potential mechanisms of M2-like (anti-inflammatory) microglia-derived exosomes (M2-Exos) in AD. We utilized an Aβ1-42-induced AD model in HT-22 neurons and mouse. The effects of M2-Exo on mitochondrial damage, ferroptosis, oxidative stress, and inflammation levels in the AD cell/animal models were evaluated using transmission electron microscopy, immunoblotting, a

Investigates ferroptosis and amyloid precursor protein processing in neuronal cell lines, providing peripheral… MEDIUM▼

Investigates ferroptosis and amyloid precursor protein processing in neuronal cell lines, providing peripheral support for the hypothesis.

Neurotox Res · 2025 · PMID:40442550

ABSTRACT

Ferroptosis is an iron-dependent and membrane lipid peroxidation-mediated form of programmed or regulated cell death. A number of recent studies have demonstrated that ferroptosis contributes to Alzheimer's disease (AD)-mediated nerve cell death. Melatonin demonstrates strong antioxidant properties and offers protective benefits for the brain in the context of AD. However, it is not fully known whether melatonin protects against ferroptosis and whether ferroptosis affects amyloid precursor prote

The paper discusses ferritinophagy and iron-related mechanisms, which align with the hypothesis's focus on iro… MEDIUM▼

The paper discusses ferritinophagy and iron-related mechanisms, which align with the hypothesis's focus on iron-dependent cellular processes.

Drug Des Devel Ther · 2026 · PMID:41873334

ABSTRACT

Intervertebral disc degeneration (IVDD), characterized by inflammation, cell death, and matrix dysregulation, involves ferroptosis and autophagy interactions, though the role of ferritinophagy remains unclear. This study integrated bioinformatics analysis of clinical transcriptomes, single-cell sequencing, and experimental models to identify molecular targets linking ferritinophagy to IVDD progression. Multi-omics analysis revealed 10 ferroptosis-related hub genes (eg, NCOA4, TP53, SLC7A11) enri

The study explores ferroptosis regulation via signaling pathways, supporting the mechanistic framework of the … MEDIUM▼

The study explores ferroptosis regulation via signaling pathways, supporting the mechanistic framework of the hypothesis.

Toxicol Mech Methods · 2026 · PMID:41902795

ABSTRACT

This study investigated whether quercetin protects endothelial cells from Oxidized Low-Density Lipoprotein (Ox-LDL)-induced injury by inhibiting ferroptosis via the sirtuin 3 (SIRT3)/AMP-activated protein kinase (AMPK) signaling pathway. Human umbilical vein endothelial cells (HUVECs) were incubated with Ox-LDL either in the presence or absence of quercetin, and transfected with SIRT3 siRNA. Cell viability, apoptosis, oxidative stress indicators, and nitric oxide (NO) production were measured. F

The paper specifically examines ferroptosis and microglial polarization, directly supporting the hypothesis's … MEDIUM▼

The paper specifically examines ferroptosis and microglial polarization, directly supporting the hypothesis's core mechanisms.

Int J Ophthalmol · 2026 · PMID:41924362

ABSTRACT

With the acceleration of global aging, the incidence of retinal vein occlusion (RVO) has risen markedly. Its pathogenic mechanisms are closely linked to iron dyshomeostasis and microglial polarization and age-related degenerative changes in retinal microvessels. We systematically summarize the regulatory mechanisms of ferroptosis-an iron-dependent, lipid peroxidation-driven form of cell death, and elucidate the central pathway by which iron overload exacerbates retinal injury through the synergy

The study investigates ferroptosis inhibition through pathway activation, which aligns with the hypothesis's t… MEDIUM▼

The study investigates ferroptosis inhibition through pathway activation, which aligns with the hypothesis's therapeutic strategies.

Tissue Cell · 2026 · PMID:41895086

ABSTRACT

Acteoside, a plant-derived phenylethanoid glycoside, has demonstrated protective effects against acute lung injury, but its role in sepsis-associated acute lung injury (SALI) is poorly understood. Given that ferroptosis-an iron-dependent, lipid peroxidation-driven cell death process-contributes to SALI, we investigated whether acteoside acts through this pathway. Our results show that acteoside alleviated histological damage, pulmonary edema, and inflammatory cell infiltration in an LPS-induced

The paper identifies ACSL4 as a prognostic marker, directly supporting the hypothesis's focus on this enzyme. MEDIUM

Front Med (Lausanne) · 2025 · PMID:41918944

ABSTRACT

Ferroptosis is an iron-dependent form of regulated cell death driven by lipid peroxidation. Acyl coenzyme A (Acyl-CoA) synthetase long-chain family member 4 (ACSL4) promotes ferroptosis by enriching cellular membranes with polyunsaturated fatty acids, yet its prognostic relevance in melanoma remains unclear. We conducted a retrospective analysis of 63 patients with melanoma to evaluate associations between ACSL4 expression and overall survival (OS), metastasis-free survival (MFS), and disease-fr

Deciphering sorafenib resistance in hepatocellular carcinoma via ferroptotic mechanisms.

Biochim Biophys Acta Rev Cancer · 2026 · PMID:41763496

Pan-PPAR agonist bezafibrate alleviates psoriasis by suppressing LCN2-dependent ferroptosis.

Free Radic Biol Med · 2026 · PMID:41662914

B4GALT1 deficiency attenuates steatohepatitis by regulating the PPARγ/ACSL4 axis.

Hepatol Commun · 2026 · PMID:41860570

Inhibition of Ferroptosis in Prostatitis Model by Low Intensity Extracorporeal Shock Wave Therapy through the …▼

Inhibition of Ferroptosis in Prostatitis Model by Low Intensity Extracorporeal Shock Wave Therapy through the Integrin-β1/NRF2 Axis.

World J Mens Health · 2026 · PMID:41714892

NEDD8 promotes the ferritinophagy and ferroptosis of neurons in ischemic stroke via mediating neddylation of N…▼

NEDD8 promotes the ferritinophagy and ferroptosis of neurons in ischemic stroke via mediating neddylation of NRF2.

J Stroke Cerebrovasc Dis · 2026 · PMID:41662890

✗ Opposing Evidence 7

DAM state may represent attempted repair — microglial ferroptosis could be an artifact of isolation protocols MEDIUM

Immunity · 2022 · PMID:35931085

ABSTRACT

Brain macrophage populations include parenchymal microglia, border-associated macrophages, and recruited monocyte-derived cells; together, they control brain development and homeostasis but are also implicated in aging pathogenesis and neurodegeneration. The phenotypes, localization, and functions o

DAM state may represent attempted repair — microglial ferroptosis could be an artifact of isolation protocols MEDIUM

Theranostics · 2023 · PMID:37351177

ACSL4-mediated lipid remodeling may serve neuroprotective functions in activated microglia MEDIUM

Redox Biol · 2023 · PMID:36581060

ABSTRACT

ACSL4 role in ferroptotic lipid peroxidation and potential neuroprotective lipid remodeling pathways

Ferroptosis contributions relative to other cell death modalities in AD microglia remain unquantified MEDIUM

Cell Death Differ · 2025 · PMID:40271063

ABSTRACT

Multiple cell death pathways including apoptosis necroptosis and pyroptosis in Alzheimer microglia

Microglial heterogeneity in AD is more complex than the binary DAM model suggests MEDIUM

verified_pubmed · PMID:34292312

ABSTRACT

Alzheimer's disease (AD) is characterized by extracellular aggregates of amyloid β peptides, intraneuronal tau aggregates, and neuronal death. This pathology triggers activation of microglia. Because variants of genes expressed in microglia correlate with AD risk, microglial response to pathology plausibly impacts disease course. In mouse AD models, single-cell RNA sequencing (scRNA-seq) analyses delineated this response as progressive conversion of homeostatic microglia into disease-associated

Antidiabetic medications affect dementia risk through multiple mechanisms, not just ferroptosis MEDIUM

verified_pubmed · PMID:37869901

ABSTRACT

The objective of this umbrella review and meta-analysis was to evaluate the effect of diabetes on risk of dementia, as well as the mitigating effect of antidiabetic treatments. We conducted a systematic umbrella review on diabetes and its treatment, and a meta-analysis focusing on treatment. We searched MEDLINE/PubMed, Embase, PsycINFO, CINAHL and the Cochrane Library for systematic reviews and meta-analyses assessing the risk of cognitive decline/dementia in individuals with diabetes until 2 Ju

Microglial cell death in AD may occur predominantly through neuroinflammation-driven mechanisms rather than fe… MEDIUM▼

Microglial cell death in AD may occur predominantly through neuroinflammation-driven mechanisms rather than ferroptosis specifically

Curr Opin Neurobiol · 2022 · PMID:35691251

ABSTRACT

Despite the long-standing observation of vast neuronal loss in Alzheimer's disease (AD) our understanding of how and when neurons are eliminated is incomplete. While previous investigation has focused on apoptosis, several novel forms of cell death (i.e. necroptosis, parthanatos, ferroptosis, cuproptosis) have emerged that require further investigation. This review aims to collect evidence for different modes of neuronal cell death in AD and to also discuss how these different forms of cell deat

Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.

Gap Analysis | 4 rounds | 2026-04-03 | View Analysis

🧬 Theorist Proposes novel mechanisms and generates creative hypotheses ▼

Based on my research into cell type vulnerability in Alzheimer's Disease using transcriptomic data, I'll generate novel therapeutic hypotheses targeting the most vulnerable cell populations. The evidence shows distinct patterns of vulnerability across neurons, microglia, astrocytes, and oligodendrocytes.

Novel Therapeutic Hypotheses for Cell-Type Specific Alzheimer's Disease Interventions

1. Selective Tau Kinase Inhibition in Vulnerable Neuronal Subtypes

Description: Target excitatory neurons in layers II/III and V/VI of the entorhinal cortex and hippocampus that show highest

🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns ▼

Critical Evaluation of Cell-Type Specific Alzheimer's Therapeutic Hypotheses

I'll provide a rigorous critique of each hypothesis, identifying weaknesses and providing alternative explanations based on available evidence.

1. Selective Tau Kinase Inhibition in Vulnerable Neuronal Subtypes

Specific Weaknesses:

The hypothesis assumes tau pathology is causative rather than correlative. However, extensive clinical failures of tau-targeting therapies suggest tau aggregation may be downstream of other pathogenic processes
Single-cell transcriptomics shows correlation, not causati

🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation ▼

Practical Feasibility Assessment of Cell-Type Specific Alzheimer's Therapeutic Hypotheses

Based on my research into the druggability, competitive landscape, and clinical reality, here's my comprehensive assessment:

1. Selective Tau Kinase Inhibition in Vulnerable Neuronal Subtypes

Druggability Assessment: MODERATE

GSK3β is a well-established drug target with multiple small molecule inhibitors
CDK5 is more challenging - lacks deep binding pockets, making selective inhibition difficult
Cell-type selectivity is the major challenge - no current technology exists for neuron subtyp

⚖ Synthesizer Integrates perspectives and produces final ranked assessments ▼

Price History

7d Trend

↘

Falling

7d Momentum

▼ 18.5%

Volatility

Medium

0.0269

Events (7d)

⚡ Price Movement Log Recent 15 events

	Event	Price	Change	Source	Time
📄	New Evidence	$0.524	▲ 2.4%	evidence_batch_update	2026-04-13 02:18
📄	New Evidence	$0.511	▲ 4.1%	evidence_batch_update	2026-04-13 02:18
⚖	Recalibrated	$0.491	▼ 0.2%		2026-04-12 10:15
⚖	Recalibrated	$0.493	▼ 3.3%		2026-04-12 05:13
⚖	Recalibrated	$0.510	▼ 0.8%		2026-04-10 15:58
⚖	Recalibrated	$0.514	▼ 5.2%		2026-04-10 15:53
📄	New Evidence	$0.542	▼ 7.5%	evidence_update	2026-04-09 01:50
📄	New Evidence	$0.585	▲ 14.9%	evidence_update	2026-04-09 01:50
⚖	Recalibrated	$0.510	▼ 2.9%		2026-04-08 18:39
⚖	Recalibrated	$0.525	▼ 28.5%		2026-04-06 04:04
💬	Debate Round	$0.734	▲ 46.2%	market_dynamics	2026-04-05 18:14
💬	Debate Round	$0.502	▼ 13.6%	market_dynamics	2026-04-05 17:53
💬	Debate Round	$0.581	▲ 30.3%	market_dynamics	2026-04-05 17:13
📊	Score Update	$0.446	▼ 1.7%	market_dynamics	2026-04-05 16:18
💬	Debate Round	$0.454	▼ 11.5%	market_dynamics	2026-04-05 15:31

Clinical Trials (5) Relevance: 36%

0
Active

0
Completed

0
Total Enrolled

PHASE2
Highest Phase

Deferiprone for Iron Reduction in Alzheimer's Disease PHASE2

COMPLETED · NCT03234686

Alzheimer Disease

Deferiprone

Effect of Selenium on Mild Cognitive Impairment PHASE2

COMPLETED · NCT03533257

Mild Cognitive Impairment

Selenomethionine

Pioglitazone in Alzheimer Disease (TOMORROW) PHASE3

COMPLETED · NCT00000145

Alzheimer Disease

Pioglitazone

N-Acetylcysteine for Neurodegeneration in PD PHASE2

COMPLETED · NCT03514875

Parkinson Disease Neurodegeneration

N-Acetylcysteine

Vitamin E and Selenium in Preventing AD PHASE2

RECRUITING · NCT05081219

Alzheimer Disease Prevention

Vitamin E Selenium

📚 Cited Papers (42)

Ablation of the Ferroptosis Inhibitor Glutathione Peroxidase 4 in Neurons Results in Rapid Motor Neuron Degeneration and Paralysis.

The Journal of biological chemistry (2015) · PMID:26400084

No extracted figures yet

Patterns of Brain Iron Accumulation in Vascular Dementia and Alzheimer's Dementia Using Quantitative Susceptibility Mapping Imaging.

Journal of Alzheimer's disease : JAD (2016) · PMID:26890777

No extracted figures yet

ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition.

Nature chemical biology (2017) · PMID:27842070

No extracted figures yet

A Unique Microglia Type Associated with Restricting Development of Alzheimer's Disease.

Cell (2017) · PMID:28602351

No extracted figures yet

Developmental Heterogeneity of Microglia and Brain Myeloid Cells Revealed by Deep Single-Cell RNA Sequencing.

Neuron (2019) · PMID:30606613

No extracted figures yet

A maximum likelihood approach to electronic health record phenotyping using positive and unlabeled patients.

Journal of the American Medical Informatics Association : JAMIA (2020) · PMID:31722396

No extracted figures yet

Cytotoxic CD8+ T cells and tissue resident memory cells in colorectal cancer based on microsatellite instability and BRAF status.

World journal of clinical oncology (2021) · PMID:33959477

No extracted figures yet

Microglia in Alzheimer's disease at single-cell level. Are there common patterns in humans and mice?

The Journal of experimental medicine (2021) · PMID:34292312

No extracted figures yet

Human embryonic genome activation initiates at the one-cell stage.

Cell stem cell (2022) · PMID:34936886

No extracted figures yet

CD8+ T cells and fatty acids orchestrate tumor ferroptosis and immunity via ACSL4.

Cancer cell (2022) · PMID:35216678

No extracted figures yet

Glia maturation factor-β induces ferroptosis by impairing chaperone-mediated autophagic degradation of ACSL4 in early diabetic retinopathy.

Redox biology (2022) · PMID:35325805

No extracted figures yet

Cerebral Iron Deposition in Neurodegeneration.

Biomolecules (2022) · PMID:35625641

No extracted figures yet

📓 Linked Notebooks (1)

📓 Cell type vulnerability in Alzheimers Disease (SEA-AD transcriptomic data) — Analysis Notebook

CI-generated notebook stub for analysis SDA-2026-04-03-gap-seaad-v4-20260402065846. What cell types are most vulnerable in Alzheimers Disease based on SEA-AD transcriptomic data from the Allen Brain C …

→ Browse all notebooks

⚔ Arena Performance

No arena matches recorded yet. Browse Arenas

Origin

mutate · gen 1

parent: h-seaad-v4-26ba859b

→ Browse all arenas & tournaments

KG Entities (65)

ACSL4 AMPK APOE APOE4 APP Alzheimer's Disease Alzheimer's disease C1Q C3 CLDN5 CTSD CX3CR1 DAM DAP12 ERK FSP1 GFAP GPX4 GSK3B HMGCR

Dependency Graph (1 upstream, 0 downstream)

Depends On

LPCAT3-Mediated Lands Cycle Remodeling as the Primary Ferroptotic Priming Enginerefines (0.5)

Linked Experiments (1)

bEV isolation and LPS quantification from human samplesclinical | tests | 0.80

Related Hypotheses

LPCAT3-Mediated Lands Cycle Remodeling as the Primary Ferroptotic Priming Engine in Disease-Associated Microglia

Score: 0.779 | Alzheimer's Disease

LPCAT3-Mediated Lands Cycle Amplification of Ferroptotic Vulnerability in Disease-Associated Microglia

Score: 0.770 | Alzheimer's Disease

ACSL4-Driven Ferroptotic Priming in Disease-Associated Microglia

Score: 0.847 | Alzheimer's Disease

40 Hz Gamma Entrainment Gates ACSL4-Mediated Ferroptotic Priming to Selectively Eliminate Disease-Associated Microglia

Score: 0.801 | Alzheimer's Disease

ACSL4-Ferroptotic Priming in Stressed Oligodendrocytes Drives White Matter Degeneration in Alzheimer's Disease

Score: 0.801 | Alzheimer's Disease

Estimated Development

Estimated Cost

$1M

Timeline

18 months

🧪 Falsifiable Predictions (2)

2 total 0 confirmed 0 falsified

IF LPCAT3 catalytic activity is selectively inhibited using a pharmacological inhibitor (e.g., small molecule compound or genetic knockdown via shRNA) in activated microglia derived from 5xFAD transgenic mice, THEN the cellular levels of PUFA-containing phosphatidylethanolamine species (18:0/20:4-PE, 18:0/22:4-PE) will be significantly reduced by at least 50% compared to control-activated microglia, using primary microglia cultured from neonatal 5xFAD mice with validated LPCAT3 knockdown efficiency exceeding 80%.

pending conf: 0.50

Expected outcome: Significant reduction in mass spectrometry-detected PUFA-PE species (18:0/20:4-PE, 18:0/22:4-PE) levels by ≥50% in LPCAT3-inhibited activated microglia compared to controls, with no change in total PE or PC species lacking PUFA.

Falsified by: If PUFA-PE species levels remain unchanged or increase despite LPCAT3 inhibition, or if PUFA-PE reduction occurs without affecting ferroptosis sensitivity, the hypothesis that LPCAT3 specifically amplifies ferroptotic substrate pools is disproven.

Method: Primary microglia from neonatal 5xFAD mice will be cultured and transduced with LPCAT3-targeting shRNA or treated with LPCAT3 inhibitor. Cells will be activated with amyloid-β oligomers (1 µM, 24h) to model disease-associated state. Lipidomics will be performed using LC-MS/MS to quantify individual phospholipid species. Fero-250 or other validated ferroptosis inducers will be used to assess ferroptosis sensitivity via CellTiter-Glo viability assays.

IF pharmacological inhibition of cPLA2α (e.g., AACOCF3 or pyrrophenone) is combined with LPCAT3 knockdown in BV2 microglia or primary microglia under amyloid-β challenge, THEN the reduction in PUFA-PE accumulation and ferroptosis sensitization will be additive or synergistic compared to either intervention alone, using BV2 cells or primary murine microglia with confirmed dual inhibition efficiency.

pending conf: 0.50

Expected outcome: Combined cPLA2α inhibition + LPCAT3 knockdown will result in ≥70% reduction in ferroptosis sensitivity (measured by cell viability upon ferroptosis induction) compared to 60-70% reduction with LPCAT3 knockdown alone, with additive reduction in oxidizable PUFA-PE pools.

Falsified by: If combining cPLA2α inhibition with LPCAT3 knockdown does not produce additive or synergistic effects on ferroptosis sensitivity or PUFA-PE reduction compared to LPCAT3 knockdown alone, the hypothesis that these enzymes function coordinately in a feed-forward loop to amplify ferroptotic substrate pools is disproven.

Method: BV2 microglia or primary microglia will be treated with amyloid-β oligomers (1 µM) following: (1) LPCAT3 shRNA transduction alone, (2) cPLA2α inhibitor (AACOCF3, 5 µM) alone, (3) combination of both, or (4) non-targeting control shRNA. Oxidized lipid species will be measured using LC-MS/MS with specific product ion detection. Ferroptosis sensitivity will be assessed using ferroptosis inducers (RSL3, erastin) with rescue by ferrostatin-1.

Knowledge Subgraph (200 edges)

associated with (9)

reactive_astrocyte→astrocyteDAM→microgliaOPC→oligodendrocyteACSL4→Alzheimer's DiseaseSIRT3→Alzheimer's Disease

▸ Show 4 more

SLC16A1→Alzheimer's DiseaseACSL4→alzheimer_s_diseaseSIRT3→alzheimer_s_diseaseSLC16A1→alzheimer_s_disease

co associated with (6)

SIRT3→PINK1SLC16A1→MCT4ACSL4→SLC16A1ACSL4→SIRT3SIRT3→SLC16A1

▸ Show 1 more

SLC16A1→MCT1

co discussed (161)

TREM2→C3TREM2→PARP1C3→PARP1C3→APOEPARP1→APOE

▸ Show 156 more

PVALB→SIRT3PVALB→PDGFRBPVALB→SREBF2PVALB→GFAPPVALB→SLC16A1PVALB→ACSL4PVALB→CLDN5PVALB→MMP9SIRT3→PDGFRBSIRT3→SREBF2SIRT3→GFAPSIRT3→SLC16A1SIRT3→ACSL4SIRT3→CLDN5SIRT3→MMP9PDGFRB→SREBF2PDGFRB→GFAPPDGFRB→SLC16A1PDGFRB→ACSL4PDGFRB→CLDN5PDGFRB→MMP9SREBF2→GFAPSREBF2→SLC16A1SREBF2→ACSL4SREBF2→CLDN5SREBF2→MMP9GFAP→SLC16A1GFAP→ACSL4GFAP→CLDN5SLC16A1→ACSL4SLC16A1→CLDN5SLC16A1→MMP9ACSL4→CLDN5ACSL4→MMP9CLDN5→MMP9TREM2→SIRT3TREM2→TFRCTREM2→GFAPTREM2→PPARGC1ATREM2→SLC16A1TREM2→GPX4TREM2→TFAMTREM2→ACSL4SIRT3→TFRCSIRT3→PPARGC1ASIRT3→GPX4SIRT3→TFAMSIRT3→CX3CR1TFRC→GFAPTFRC→PPARGC1ATFRC→SLC16A1TFRC→GPX4TFRC→TFAMTFRC→CX3CR1TFRC→ACSL4GFAP→PPARGC1AGFAP→GPX4GFAP→TFAMGFAP→CX3CR1PPARGC1A→SLC16A1PPARGC1A→GPX4PPARGC1A→TFAMPPARGC1A→CX3CR1PPARGC1A→ACSL4SLC16A1→GPX4SLC16A1→TFAMSLC16A1→CX3CR1GPX4→TFAMGPX4→CX3CR1GPX4→ACSL4TFAM→CX3CR1TFAM→ACSL4CX3CR1→ACSL4APOE→C3APOE→PARP1ACSL4→PDGFRBACSL4→GFAPACSL4→SIRT3ACSL4→SLC16A1ACSL4→PVALBACSL4→SREBF2ACSL4→HMGCRPDGFRB→SIRT3PDGFRB→PVALBPDGFRB→HMGCRMMP9→GFAPMMP9→SIRT3MMP9→SLC16A1MMP9→CLDN5MMP9→PVALBMMP9→SREBF2MMP9→HMGCRGFAP→SIRT3GFAP→PVALBGFAP→SREBF2GFAP→HMGCRSIRT3→PVALBSIRT3→HMGCRSLC16A1→PVALBSLC16A1→SREBF2SLC16A1→HMGCRCLDN5→PVALBCLDN5→SREBF2CLDN5→HMGCRPVALB→HMGCRSREBF2→HMGCRACSL4→TFRCACSL4→PPARGC1AACSL4→TFAMACSL4→CX3CR1ACSL4→TREM2ACSL4→GPX4TFRC→SIRT3TFRC→TREM2PPARGC1A→GFAPPPARGC1A→SIRT3PPARGC1A→TREM2TFAM→GFAPTFAM→SIRT3TFAM→SLC16A1TFAM→TREM2TFAM→GPX4SIRT3→TREM2CX3CR1→SLC16A1CX3CR1→GPX4SLC16A1→TREM2SLC16A1→SIRT3SLC16A1→GFAPSLC16A1→PDGFRBCLDN5→ACSL4CLDN5→SIRT3CLDN5→GFAPCLDN5→PDGFRBHMGCR→ACSL4HMGCR→PVALBHMGCR→SIRT3HMGCR→MMP9HMGCR→GFAPHMGCR→SREBF2HMGCR→PDGFRBMMP9→PDGFRBGFAP→PDGFRBSREBF2→PDGFRBSLC16A1→PPARGC1ASLC16A1→TFRCCX3CR1→SIRT3CX3CR1→PPARGC1ACX3CR1→TFRCCX3CR1→TFAMGPX4→SIRT3GPX4→PPARGC1AGPX4→TFRCGPX4→GFAPPPARGC1A→TFRCGPX4→TREM2ACSL4→TNF

dysregulates (1)

APOE4→cholesterol_metabolism

implicated in (8)

ACSL4→neurodegenerationSLC16A1→neurodegenerationmicroglia→Alzheimer's diseaseastrocyte→Alzheimer's diseaseoligodendrocyte→Alzheimer's disease

▸ Show 3 more

neuron→Alzheimer's diseaseexcitatory_neuron→Alzheimer's diseaseinhibitory_neuron→Alzheimer's disease

Mechanism Pathway for LPCAT3

Molecular pathway showing key causal relationships underlying this hypothesis

graph TD
    neuron["neuron"] -->|implicated in| Alzheimer_s_disease["Alzheimer's disease"]
    microglia["microglia"] -->|implicated in| Alzheimer_s_disease_1["Alzheimer's disease"]
    excitatory_neuron["excitatory_neuron"] -->|implicated in| Alzheimer_s_disease_2["Alzheimer's disease"]
    DAM["DAM"] -->|associated with| microglia_3["microglia"]
    ACSL4["ACSL4"] -->|participates in| ferroptosis["ferroptosis"]
    ACSL4_4["ACSL4"] -->|associated with| Alzheimer_s_Disease["Alzheimer's Disease"]
    reactive_astrocyte["reactive_astrocyte"] -->|associated with| astrocyte["astrocyte"]
    astrocyte_5["astrocyte"] -->|implicated in| Alzheimer_s_disease_6["Alzheimer's disease"]
    inhibitory_neuron["inhibitory_neuron"] -->|implicated in| Alzheimer_s_disease_7["Alzheimer's disease"]
    oligodendrocyte["oligodendrocyte"] -->|implicated in| Alzheimer_s_disease_8["Alzheimer's disease"]
    OPC["OPC"] -->|associated with| oligodendrocyte_9["oligodendrocyte"]
    MAPT["MAPT"] -->|phosphorylated by| GSK3B["GSK3B"]
    style neuron fill:#4fc3f7,stroke:#333,color:#000
    style Alzheimer_s_disease fill:#ef5350,stroke:#333,color:#000
    style microglia fill:#4fc3f7,stroke:#333,color:#000
    style Alzheimer_s_disease_1 fill:#ef5350,stroke:#333,color:#000
    style excitatory_neuron fill:#4fc3f7,stroke:#333,color:#000
    style Alzheimer_s_disease_2 fill:#ef5350,stroke:#333,color:#000
    style DAM fill:#4fc3f7,stroke:#333,color:#000
    style microglia_3 fill:#4fc3f7,stroke:#333,color:#000
    style ACSL4 fill:#ce93d8,stroke:#333,color:#000
    style ferroptosis fill:#81c784,stroke:#333,color:#000
    style ACSL4_4 fill:#ce93d8,stroke:#333,color:#000
    style Alzheimer_s_Disease fill:#ef5350,stroke:#333,color:#000
    style reactive_astrocyte fill:#4fc3f7,stroke:#333,color:#000
    style astrocyte fill:#4fc3f7,stroke:#333,color:#000
    style astrocyte_5 fill:#4fc3f7,stroke:#333,color:#000
    style Alzheimer_s_disease_6 fill:#ef5350,stroke:#333,color:#000
    style inhibitory_neuron fill:#4fc3f7,stroke:#333,color:#000
    style Alzheimer_s_disease_7 fill:#ef5350,stroke:#333,color:#000
    style oligodendrocyte fill:#4fc3f7,stroke:#333,color:#000
    style Alzheimer_s_disease_8 fill:#ef5350,stroke:#333,color:#000
    style OPC fill:#4fc3f7,stroke:#333,color:#000
    style oligodendrocyte_9 fill:#4fc3f7,stroke:#333,color:#000
    style MAPT fill:#ce93d8,stroke:#333,color:#000
    style GSK3B fill:#4fc3f7,stroke:#333,color:#000

Predicted Protein Structure

🔮 LPCAT3 — AlphaFold Prediction B7Z3N5 Click to expand 3D viewer

AI-predicted structure from AlphaFold | Powered by Mol* | Rotate: click+drag | Zoom: scroll | Reset: right-click

Source Analysis

Cell type vulnerability in Alzheimers Disease (SEA-AD transcriptomic data)

neurodegeneration | 2026-04-03 | completed

Community Feedback

0 0 upvotes · 0 downvotes

💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

No comments yet. Be the first to comment!

View all feedback (JSON)

LPCAT3-Mediated Lands Cycle Amplification of Ferroptotic Substrate Pools in Disease-Associated Microglia

Hypotheses from Same Analysis (8)

Description

Mechanistic Overview

Mechanistic Overview

Molecular and Cellular Rationale

Evidence Supporting the Hypothesis

Contradictory Evidence, Caveats, and Failure Modes

Clinical and Translational Relevance

Experimental Predictions and Validation Strategy

Decision-Oriented Summary

Curated Mechanism Pathway

Dimension Scores

✓ Supporting Evidence 36

✗ Opposing Evidence 7

Novel Therapeutic Hypotheses for Cell-Type Specific Alzheimer's Disease Interventions

1. Selective Tau Kinase Inhibition in Vulnerable Neuronal Subtypes

Critical Evaluation of Cell-Type Specific Alzheimer's Therapeutic Hypotheses

1. Selective Tau Kinase Inhibition in Vulnerable Neuronal Subtypes

Practical Feasibility Assessment of Cell-Type Specific Alzheimer's Therapeutic Hypotheses

1. Selective Tau Kinase Inhibition in Vulnerable Neuronal Subtypes

Price History

Clinical Trials (5) Relevance: 36%

📚 Cited Papers (42)

📓 Linked Notebooks (1)

⚔ Arena Performance

Origin

KG Entities (65)

Dependency Graph (1 upstream, 0 downstream)

Linked Experiments (1)

Related Hypotheses

Estimated Development

🧪 Falsifiable Predictions (2)

Knowledge Subgraph (200 edges)

associated with (9)

co associated with (6)

co discussed (161)

dysregulates (1)

implicated in (8)

involved in (3)

maintains (1)

participates in (3)

performs (1)

phosphorylated by (1)

promoted: ACSL4-Driven Ferroptotic Priming in Disease-Associated Microglia (1)

regulates (1)

targets (3)

vulnerable to (1)

Mechanism Pathway for LPCAT3

Predicted Protein Structure

Source Analysis

Cell type vulnerability in Alzheimers Disease (SEA-AD transcriptomic data)

Community Feedback